161 related articles for article (PubMed ID: 33457100)
1. Multiverse of immune microenvironment in metastatic colorectal cancer.
Van den Eynde M; Mlecnik B; Bindea G; Galon J
Oncoimmunology; 2020 Sep; 9(1):1824316. PubMed ID: 33457100
[TBL] [Abstract][Full Text] [Related]
2. The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients.
Van den Eynde M; Mlecnik B; Bindea G; Fredriksen T; Church SE; Lafontaine L; Haicheur N; Marliot F; Angelova M; Vasaturo A; Bruni D; Jouret-Mourin A; Baldin P; Huyghe N; Haustermans K; Debucquoy A; Van Cutsem E; Gigot JF; Hubert C; Kartheuser A; Remue C; Léonard D; Valge-Archer V; Pagès F; Machiels JP; Galon J
Cancer Cell; 2018 Dec; 34(6):1012-1026.e3. PubMed ID: 30537506
[TBL] [Abstract][Full Text] [Related]
3. Metastasis immune-based scores predict patient survival.
Mlecnik B; Bindea G; Van den Eynde M; Galon J
Oncoimmunology; 2020 Aug; 9(1):1806000. PubMed ID: 32923167
[TBL] [Abstract][Full Text] [Related]
4. Tumor spread or siege immunity: dissemination to distant metastasis or not.
Bindea G; Mlecnik B; Galon J
Oncoimmunology; 2021 Apr; 10(1):1919377. PubMed ID: 33996269
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.
Mlecnik B; Van den Eynde M; Bindea G; Church SE; Vasaturo A; Fredriksen T; Lafontaine L; Haicheur N; Marliot F; Debetancourt D; Pairet G; Jouret-Mourin A; Gigot JF; Hubert C; Danse E; Dragean C; Carrasco J; Humblet Y; Valge-Archer V; Berger A; Pagès F; Machiels JP; Galon J
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922789
[TBL] [Abstract][Full Text] [Related]
6. Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patients.
Baldin P; Van den Eynde M; Mlecnik B; Galon J
Oncoimmunology; 2020 Oct; 9(1):1826133. PubMed ID: 33110705
[TBL] [Abstract][Full Text] [Related]
7. Immunodivergence in Metastatic Colorectal Cancer.
de Andrea CE; Schalper KA; Sanmamed MF; Melero I
Cancer Cell; 2018 Dec; 34(6):876-878. PubMed ID: 30537510
[TBL] [Abstract][Full Text] [Related]
8. An Efficient Prognostic Immune Scoring System For Colorectal Cancer Patients With Peritoneal Metastasis.
Zhao Y; Chen C; Xu X; Ge X; Ding K; Zheng S; Wang J; Sun L
Oncoimmunology; 2021 Mar; 10(1):1901464. PubMed ID: 33796414
[TBL] [Abstract][Full Text] [Related]
9. [Immunoscore and Its Predictive Value for Colorectal Cancer].
Závadová E; Špaček J; Vočka M; Konopásek B; Fučíková T; Netíková I; Dundr P; Skálová H; Petruželka L
Klin Onkol; 2015; 28 Suppl 4():4S82-5. PubMed ID: 26647895
[TBL] [Abstract][Full Text] [Related]
10. Usefulness and robustness of Immunoscore for personalized management of cancer patients.
Marliot F; Pagès F; Galon J
Oncoimmunology; 2020 Oct; 9(1):1832324. PubMed ID: 33194318
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Immune Microenvironment Between Colon and Liver Metastatic Tissue in Colon Cancer Patients with Liver Metastasis.
Zhou SN; Pan WT; Pan MX; Luo QY; Zhang L; Lin JZ; Zhao YJ; Yan XL; Yuan LP; Zhang YX; Yang DJ; Qiu MZ
Dig Dis Sci; 2021 Feb; 66(2):474-482. PubMed ID: 32193860
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive values of the immunoscore in patients with rectal cancer.
Anitei MG; Zeitoun G; Mlecnik B; Marliot F; Haicheur N; Todosi AM; Kirilovsky A; Lagorce C; Bindea G; Ferariu D; Danciu M; Bruneval P; Scripcariu V; Chevallier JM; Zinzindohoué F; Berger A; Galon J; Pagès F
Clin Cancer Res; 2014 Apr; 20(7):1891-9. PubMed ID: 24691640
[TBL] [Abstract][Full Text] [Related]
14. The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.
Zeitoun G; Sissy CE; Kirilovsky A; Anitei G; Todosi AM; Marliot F; Haicheur N; Lagorce C; Berger A; Zinzindohoué F; Galon J; Scripcariu V; Pagès F
Chirurgia (Bucur); 2019; 114(2):152-161. PubMed ID: 31060646
[TBL] [Abstract][Full Text] [Related]
15. No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study.
Ascierto PA; Marincola FM; Fox BA; Galon J
Oncoimmunology; 2020 Oct; 9(1):1826132. PubMed ID: 33194317
[TBL] [Abstract][Full Text] [Related]
16. Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes.
Guo G; Wang Y; Zhou Y; Quan Q; Zhang Y; Wang H; Zhang B; Xia L
J Immunother Cancer; 2019 Jul; 7(1):179. PubMed ID: 31300050
[TBL] [Abstract][Full Text] [Related]
17. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy.
Halama N; Michel S; Kloor M; Zoernig I; Pommerencke T; von Knebel Doeberitz M; Schirmacher P; Weitz J; Grabe N; Jäger D
Cancer Immun; 2009 Feb; 9():1. PubMed ID: 19226101
[TBL] [Abstract][Full Text] [Related]
18. Evolution of Metastases in Space and Time under Immune Selection.
Angelova M; Mlecnik B; Vasaturo A; Bindea G; Fredriksen T; Lafontaine L; Buttard B; Morgand E; Bruni D; Jouret-Mourin A; Hubert C; Kartheuser A; Humblet Y; Ceccarelli M; Syed N; Marincola FM; Bedognetti D; Van den Eynde M; Galon J
Cell; 2018 Oct; 175(3):751-765.e16. PubMed ID: 30318143
[TBL] [Abstract][Full Text] [Related]
19. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.
Mlecnik B; Bindea G; Kirilovsky A; Angell HK; Obenauf AC; Tosolini M; Church SE; Maby P; Vasaturo A; Angelova M; Fredriksen T; Mauger S; Waldner M; Berger A; Speicher MR; Pagès F; Valge-Archer V; Galon J
Sci Transl Med; 2016 Feb; 8(327):327ra26. PubMed ID: 26912905
[TBL] [Abstract][Full Text] [Related]
20. High epidermal growth factor receptor expression in metastatic colorectal cancer lymph nodes may be more prognostic of poor survival than in primary tumor.
Deng Y; Kurland BF; Wang J; Bi J; Li W; Rao S; Lan P; Lin T; Lin E
Am J Clin Oncol; 2009 Jun; 32(3):245-52. PubMed ID: 19451802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
